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A substantial proportion of patients with common variable immunodeficiency (CVID) have
inflammatory and autoimmune complications of unknown etiology. We have previously
shown that systemic inflammation in CVID correlates with their gut microbial dysbiosis.
The gut microbiota dependent metabolite trimethylamine N-oxide (TMAO) has been
linked to several metabolic and inflammatory disorders, but has hitherto not been
investigated in relation to CVID. We hypothesized that TMAO is involved in systemic
inflammation in CVID. To explore this, we measured plasma concentrations of TMAO,
inflammatory markers, and lipopolysaccharide (LPS) in 104 CVID patients and 30
controls. Gut microbiota profiles and the bacterial genes CutC and CntA, which encode
enzymes that can convert dietary metabolites to trimethylamine in the colon, were
examined in fecal samples from 40 CVID patients and 86 controls. Furthermore, a
food frequency questionnaire and the effect of oral antibiotic rifaximin on plasma TMAO
concentrations were explored in these 40 patients. We found CVID patients to have
higher plasma concentrations of TMAO than controls (TMAO 5.0 [2.9–8.6] vs. 3.2
[2.2–6.3], p = 0.022, median with IQR). The TMAO concentration correlated positively
with tumor necrosis factor (p= 0.008, rho= 0.26), interleukin-12 (p= 0.012, rho= 0.25)
and LPS (p= 0.034, rho= 0.21). Dietary intake of meat (p= 0.678), fish (p= 0.715), egg
(p = 0.138), dairy products (p = 0.284), and fiber (p = 0.767) did not significantly impact
on the TMAO concentrations in plasma, nor did a 2-week course of the oral antibiotic
rifaximin (p = 0.975). However, plasma TMAO concentrations correlated positively with
gut microbial abundance of Gammaproteobacteria (p = 0.021, rho = 0.36). Bacterial
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gene CntA was present in significantly more CVID samples (75%) than controls (53%),
p = 0.020, potentially related to the increased abundance of Gammaproteobacteria in
these samples. The current study demonstrates that elevated TMAO concentrations
are associated with systemic inflammation and increased gut microbial abundance of
Gammaproteobacteria in CVID patients, suggesting that TMAO could be a link between
gut microbial dysbiosis and systemic inflammation. Gut microbiota composition could
thus be a potential therapeutic target to reduce systemic inflammation in CVID.
Keywords: TMAO, CVID, gut microbiota, immunodeficiency, inflammation, CutC, CntA, diet
INTRODUCTION
Common variable immunodeficiency (CVID) is the most
common symptomatic primary immunodeficiency among adults
with an estimated prevalence of between 1:25,000 and 1:50,000
(1), comprising a clinically and immunologically heterogeneous
group. A maturation defect in the B-cell development to plasma
cells results in impaired production of immunoglobulins (Ig),
leading to the clinical hallmark of CVID; recurrent infections
with encapsulated bacteria in the respiratory tract. In addition,
∼70% of CVID patients have autoimmune and inflammatory
complications (2, 3), associated with persistent systemic
inflammation and immune activation, reflecting abnormalities
in other immune cells such as monocytes/macrophages and
T-cells (4). At present, however, the mechanisms leading to
systemic sterile inflammation and autoimmunity in CVID are
not fully understood.
The gut microbiota composition has been linked to systemic
inflammation and metabolic disturbances in various systemic
metabolic and autoimmune disorders (5–7). We have previously
shown that gut microbial composition is related to systemic
inflammation and autoimmunity in CVID. Particularly, the
relative abundance of certain key groups of bacteria, which
included increased levels of Gammaproteobacteria, were
associated with systemic immune activation in CVID (8).
However, the mechanisms by which an altered gut microbiota
may translate into systemic inflammation in these patients are
not clear.
A number of studies, primarily in atherosclerosis and related
metabolic disorders, have shown an association between the
gut microbiota dependent trimethylamine N-oxide (TMAO)
and systemic inflammation (9–11). The TMAO precursor
trimethylamine (TMA) can be formed from dietary metabolites
via microbiota dependent pathways in the gut. Bacterial enzymes
such as carnitine oxygenase (CntA) and choline-TMA lyase
(CutC) can convert carnitine and choline to TMA in the
colon (12). Carnitine can also be converted to the intermediate
metabolite γ-butyrobetaine (γBB) in the small intestine, before
conversion to TMA in the colon (Figure 1A) (13). Meat, fish,
Abbreviations: BMI, body mass index; CntA, carnitine oxygenase; CutC, choline-
TMA lyase; CVID, Common variable immunodeficiency; FFQ, food frequency
questionnaire; Ig, immunoglobulins; IL, interleukin; LPS, lipopolysaccharide;
TMA, trimethylamine; TMAO, trimethylamine N-oxide; TML, trimethyllysine;
TNF, tumor necrosis factor; γBB, γ-butyrobetaine.
and eggs are particularly rich in choline, whereas red meat and
dairy products are the main sources of carnitine from the diet.
In addition, carnitine can be endogenously synthesized from
trimethyllysine via γBB (14). TMA is subsequently absorbed from
the colon and translocated to the liver via the portal circulation,
where it is oxidized to trimethylamine N-oxide (TMAO) by
flavin-containing monooxygenases (Figure 1A).
We hypothesized that TMAO could represent a link between
altered gut microbiota and systemic inflammation in CVID.
To explore this hypothesis, we measured TMAO and other
metabolites in the carnitine-TMAO pathway in CVID patients
and healthy controls, and compared these metabolites to markers
of systemic inflammation, gut microbiota composition and
diet. In addition, we explored bacterial genes suggested to
encode catalytic enzymes involved in the TMA production;




The Regional Committee for Medical and Research Ethics
approved the study protocol. All study participants signed a
written, informed consent. The work described has been carried
out in accordance with the Declaration of Helsinki.
Patient and Control Cohorts
CVID patients were recruited from the outpatient clinics at
the Section of Clinical Immunology and Infectious Diseases,
Oslo University Hospital, Rikshospitalet. CVID was defined as
decreased serum levels of IgG, in addition to IgA and/or IgM
by a minimum of two standard deviations below the mean for
age, and exclusion of other causes of hypogammaglobulinemia
(Primary immunodeficiency diseases. Report of an IUIS
Scientific Committee. International Union of Immunological
Societies. Clin Exp Immunol. 1999) (15). CVID subgroups
were classified as “Infection only” or “Complications” based on
criteria previously defined (3), however, CVID enteropathy was
defined as persistent diarrhea after exclusion of gastrointestinal
infection (8).
Blood Sampling Protocol
Peripheral venous blood was collected into sterile blood
collection tubes with EDTA as an anticoagulant. The tubes
were immediately immersed in melting ice and subsequently
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FIGURE 1 | (A,B) Microbiota dependent pathways for trimethylamine N-oxide (TMAO) formation in immunocompetent individuals and CVID patients. (A)
Immunocompetent individuals. Carnitine, betaine, and choline are mostly acquired through diet, and are metabolized by gut microbes to the TMAO precursor
trimethylamine (TMA). Diet containing TMAO precursors are here symbolized by egg, meat, and shellfish. (1) Bacterial enzymes can convert dietary metabolites to
TMA in the colon. These catalytic enzymes are encoded by bacterial genes, e.g., CutC (choline-TMA lyase) and CntA (carnitine oxygenase). (2) Carnitine can also be
converted to the intermediate metabolite γ-butyrobetaine (γBB) in the small intestine, before conversion to TMA in the colon. TMA is passively absorbed from the gut
to the portal circulation and delivered to the liver, where it is oxidized by flavin-containing monooxygenases (predominantly FMO3) to TMAO. Increased plasma levels
of TMAO has previously been linked to systemic inflammation. (B) In CVID, there is an abundance of Gammaproteobacteria in the gut as part of an overall gut
microbial dysbiosis. They have increased levels of catalytic enzymes CutC and CntA in the gut and elevated concentrations of TMAO in plasma. Increased levels of
LPS correlate with raised TMAO, further associating with increased inflammatory markers TNF and IL-12. Dietary intake of table sugar correlates positively with TMAO
whereas intake of red wine has a negative association with TMAO.
centrifuged within 15min at 2,000 g for 20min to obtain platelet-
poor plasma. Plasma was stored at−80◦C in multiple aliquots.
Analyses of Inflammatory Markers
Plasma levels of tumor necrosis factor (TNFα) and interleukin
(IL)-6, IL-8, and IL-12 were analyzed using a multiplex
cytokine assay (Bio-Plex Human Cytokine Plex Panel; Bio-Rad
Laboratories Inc., Hercules, CA). The samples were analyzed
on a Multiplex Analyzer (Bio-Rad Laboratories) according to
instructions from the manufacturer.
Measurement of Carnitine, TMAO, and
Related Metabolites
Free carnitine and γBB were analyzed in plasma using MS/MS
as described previously (16) with some modifications of
the high-performance liquid chromatography conditions
(Supplementary Methods). Stable isotope dilution liquid
chromatography–tandem mass spectrometry (LC/MS/MS) was
used for the quantification of TMAO, choline, and betaine in the
same plasma samples (Supplementary Methods).
LPS Analysis
LPS was analyzed by Limulus Amebocyte Lysate chromogenic
assay (Lonza, Walkersville, MD) according to the manufacturer’s
instructions, with the following modifications: In the 104 CVID
patients and 30 controls, samples were diluted 10-fold to avoid
interference with background color, and preheated to 68◦C
for 10min prior to analyses to dissolve immune complexes as
previously described (8, 17).
Microbiota Analyses
Participants collected stool samples at home within 24 h prior
to their hospital visit, or alternatively at the hospital, with a
standardized collection device (18). The stool samples were then
transferred by the participants to stool collection tubes with
Stool DNA Stabilizer (Stratec Biomedical, Birkenfeld, Germany)
(19). Samples were stored at minimum −20◦C according to
the manufacturer’s recommendations until DNA extraction.
Bacterial DNA was extracted using the PSP Spin Stool DNA Plus
Kit (Stratec) before being subjected to amplification of the 16S
ribosomal RNA gene with dual-indexed barcodes according to an
established protocol (20), followed by sequencing on an Illumina
MiSeq (San Diego, CA; Supplementary Methods).
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To assess bacteria with TMA producing potential we applied
qPCR DNA assays targeting CntA and CutC using modified
primers described by Rath et al. (12). Briefly, 30 ng DNA was
analyzed using HOT FIREPol EvaGreen qPCR Mix Plus (Solis,
BioDyne, Brumath Cedex, France) and Applied Biosystems
7900HT, primer concentration and thermal cycles as described
(12). All products in the melting curve with a melting
temperature above 78◦C were considered a CntA product. CutC
levels were normalized to 16S rRNA gene levels and presented
as ddCt.
Food Frequency Questionnaire
CVID patients were asked to complete a self-administrated,
validated Norwegian food frequency questionnaire designed
to reflect dietary habits over the past year (21, 22). The
questionnaire offers multiple choice alternatives and also the
opportunity to provide supplementary information regarding
specific dietary restrictions or habits. It covers 180 food items and
has serving size alternatives specified in households units, which
is then converted to grams per day using a software developed at
the Institute for Nutrition Research, University of Oslo (21).
Statistical Analyses
The datasets for TMAO pathway metabolites were not normally
distributed and so the data was log transformed. Where normal
distribution was achieved, we continued with multivariate
testing and where normal distribution was not achieved, we
applied Mann–Whitney non-parametric testing. Fisher’s exact
test was used for categorical variables. Depending on the data
distribution, we performed correlation analyses with either
Spearman’s rank correlation test (correlation coefficient rho) or
Pearson’s correlation test (correlation coefficient r). Additionally,
stepwise linear regression analysis was performed to adjust
for age and sex. For the longitudinal data, we compared
datasets from three different time points using the Friedman
test. Univariate Repeated measures ANOVA (UNIANOVA) was
used to assess the effect of treatment (rifaximin), focusing on
the interaction between time and treatment group for TMAO.
Calculations were performed in SPSS (version 24, IBM, NY).
RESULTS
Patient Characteristics
We consecutively collected plasma samples from 104 CVID
patients over 13 months from the outpatient clinic at Section of
Clinical Immunology and Infectious Diseases, Oslo University
Hospital Rikshospitalet, and included 30 healthy controls as
previously described (8). In addition, stool samples, blood
samples, and food frequency questionnaire (FFQ) from 40 CVID
patients (FFQ = 38 patients) from a preceding intervention trial
(23) were included for sub-analysis. In CVID patients included
for gut microbiota analyses, the use of antibiotics in the last
12 weeks was an exclusion criterion. Patients’ characteristics
are given for both cohorts in Table 1, Supplementary Table 1,
and Supplementary Methods. Thirty-two CVID patients were
included in both cohorts, but at different time points (8, 23).
The 86 controls used in the analyses of CutC and CntA
TABLE 1 | Background characteristics for CVID cohorts and healthy controls.
Main cohort Subset cohortd
CVID Controls P-valueb CVID
n = 104 n = 30 n = 40
Age in years, mean± SD 46 ± 15 47 ± 13 0.73c 48 ± 12
Female, n (%) 51 (49) 14 (47) 0.84d 25 (63)
BMI, mean ± SD 24 ± 4 24 ± 3 0.97c 26 ± 5
IVIGa, n (%) 19 (18) – – 6 (15)
SCIG, n (%) 76 (73) – – 30 (75)
IVIG and SCIG, n (%) 7 (7) – – 4 (10)
Infection only, n (%) 25 (24) – – 8 (20)
Non-infectious
complications, n (%)
79 (76) – – 32 (80)
IVIG, Intravenous immunoglobulins; SCIG, Subcutaneous immunoglobulin; BMI, Body
Mass Index. aTwo CVID patients in the Main cohort did not receive any immunoglobulin
substitution. bP-value is given for CVID (n = 104) vs. Controls. cMann–Whitney Test.
dFisher’s exact test. eThe subset cohort is mainly used for association analysis and only
have control group for the bacterial gene analysis (See Supplementary Methods).
in stool samples did not have corresponding blood samples
(Supplementary Methods).
Metabolites in the Carnitine-TMAO
Pathway in CVID and Healthy Controls
CVID patients (n = 104) had significantly elevated plasma
concentrations of TMAO compared to healthy controls
(Figure 2A). The TMA precursors carnitine, choline, and
betaine, as well as the intermediate metabolite y-BB, were also
significantly increased in CVID patients compared to healthy
controls (Figures 2B–E). The seven outliers in the CVID group
(with the highest plasma concentration of TMAO in Figure 2A)
were tested with a gene panel for monogenic disease in relation
to their primary immunodeficiency (24), but were all negative.
To study the temporal course and stability of carnitine-
TMAO pathway metabolites, we measured the concentrations
in 20 CVID patients (mean age 51.2 years ± 11.8 [SD], 13
[65%] females) three times over 8 weeks. Sixteen patients
completed all three measurements. Applying the Friedman test,
we discovered no significant changes in concentrations of TMAO
(p = 0.444), carnitine (p = 0.144), betaine (p = 0.174), choline
(p = 0.472), or y-BB (p = 0.646) during temporal testing
(Supplementary Figure 1).
TMAO in Relation to Systemic
Inflammation
We and others have previously demonstrated increased
inflammatory cytokines such as IL-6, IL-8, IL-12, and
TNFα in CVID (25–27). These cytokines were all markedly
elevated in the 104 CVID patients compared to controls
(Supplementary Table 2) (8). We therefore selected these
inflammatory markers to explore the association between
systemic inflammation and TMAO. Plasma TMAO was
positively associated with plasma levels of TNFα and IL-12
(Figures 3A,B), but not with IL-6 (p= 0.263, rho= 0.11) or IL-8
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FIGURE 2 | (A–E) TMAO and TMAO pathway metabolite levels in CVID patients and controls. Plasma levels of (A) TMAO, (B) carnitine, (C) betaine, (D) choline, (E)
y-butyrobetaine in common variable immunodeficiency (CVID) patients (n = 104) and healthy controls (n = 30). P-values corrected for age and sex using stepwise
linear regression analyses. Each dot represents one individual; bars represent median levels with interquartile range.
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FIGURE 3 | (A,B) Correlations between TMAO and inflammatory markers.
Plasma levels of TMAO correlate positively with (A) TNFα and (B) IL-12 in CVID
patients (n = 104). Two-tailed p-values were calculated using Spearman’s rank
correlation.
(p = 0.214, rho = 0.12). Data on other measured cytokines and
their association to TMAO are shown in Supplementary Table 3.
Metabolites of the Carnitine-TMAO
Pathway in Relation to Gut Microbiota
Using existing data on gut microbiota composition from a
subset of the CVID patients (n = 40) (23), we explored if
specific bacterial taxa previously found to differentiate between
CVID patients and healthy controls correlated with TMAO
pathway metabolites in plasma sampled at the same time point.
These included the ten taxa making up the CVID dysbiosis
index found to capture CVID dysbiosis in the gut: Bacilli,
Dorea, Roseburia, Gammaproteobacteria (increased in CVID),
and Bifidobacterium, Odoribacteracea, Christensenellaceae,
Blautia, Sutterella, Desulfovibrionacea (reduced in CVID) (8). In
addition, we included five taxa identified to differ between CVID
and healthy controls in another publication using a different
statistical approach (ANCOM): Hungatella, Flavonifractor,
Veillonella, and Escherichia-Shigella (increased in CVID) and
Christensenellaceae R-7 group (reduced in CVID) (28). The
relative abundance of Gammaproteobacteria in stool samples
from CVID patients correlated positively with concentrations of
TMAO in plasma (Figure 4A). On genus level, we found positive
correlations between abundance of Escherichia-Shigella in stool
samples and plasma concentrations of TMAO (Figure 4B) and
y-BB (p = 0.046, r = 0.32) in CVID patients. Both of these
taxa were increased in CVID patients compared to controls in
previous publications from our group (Supplementary Table 4).
Blautia, a Gram positive bacterial genus previously shown to be
reduced in CVID patients, was negatively correlated with the
TMA precursor betaine (p= 0.037, r =−0.33).
Bacterial Genes, CutC and CntA, in Stool
Samples
Bacterial genes that have been suggested to encode enzymes
responsible for TMA production (29), CutC and CntA, were
measured in stool samples from 40 CVID patients and 85
age-, sex, and body mass index (BMI)-matched controls
(Supplementary Methods). These bacterial genes have also
been reported to be associated with increased abundance of
Gammaproteobacteria, demonstrated to be enriched in the gut
microbiota from CVID patients (Supplementary Table 4). In a
previous study, CntA was detected in only 26.0% of human
samples whereas CutC was found in all human samples (12). Due
to the anticipated low number of individuals that would have
CntA present, we therefore compared the number of individuals
that had CntA present in the two groups. Using qPCR on DNA
stool samples, we found that CntA was present in significantly
more CVID samples (n= 30, 75%), than controls (n= 45, 53%),
p = 0.020 (Fisher’s exact test, Figure 5A). As expected, CutC
was present in all samples. For CutC we went on to measuring
gene expression (ddCT) and found an increase in CutC gene
expression in CVID patients compared to controls, p = 0.003
(Figure 5B). To conclude, both TMA producing bacterial genes;
CutC and CntA, seem to be more prevalent in stool samples from
CVID patients compared to controls.
We went on to exploring if there was any correlation
between the expression of CutC in stool samples and the
taxa making up the CVID dysbiosis index or the other the
five taxa differing between CVID patients and controls (as
defined above). We found that CutC levels were negatively
correlated with Bifidobacterium (p = 0.04, rho = −0.33) and
Bacilli (p = 0.028, rho = −0.35), but positively correlated with
Hungatella (p = 0.003, rho = 0.46). Bifidobacterium is thought
to have health-promoting properties and is used in probiotic
supplements (30). We have previously found very low abundance
of Bifidobacterium in CVID patients compared to controls (8),
and the negative correlation with CutC could suggest that in
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FIGURE 4 | (A,B) Abundant taxa in CVID gut microbiota correlating with TMAO. (A) Gammaproteobacteria and (B) Escherichia-Shigella, taxa found in abundance in
the gut microbiota of CVID patients, correlate positively with plasma levels of TMAO (n = 40). In panel (A) one outlier is not shown (Gammaproteobacteria 0.5, TMAO
1.4µM). Two-tailed p-values were calculated using Spearman’s rank correlation.
FIGURE 5 | (A,B) Bacterial genes CntA and CutC in stool samples from CVID patients and controls. Using qPCR on DNA stool samples, CntA and CutC expression
was explored in 40 CVID patients and 86 age-, sex, and BMI-matched controls. (A) CntA is expressed as a percentage of the number of individuals with CntA present
in the two groups, Fisher’s exact test. (B) CutC is presented as ddCT gene expression (CutC levels normalized to 16S level), results shown as median and IQR
(Mann–Whitney). Three data points are outside the axis limits; one in the control group (ddCT 19.6) and two among the CVID patients (ddCT 10.8 and 30.5,
respectively).
CVID patients, TMA producing bacteria are increased at the
expense of beneficial gut bacteria such as Bifidobacterium.
TMAO in Relation to LPS and Serum IgA
Levels
We have previously shown that there are increased amounts of
the microbial product LPS in the plasma of patients with CVID
(n = 104, Supplementary Table 2) (8), potentially contributing
to systemic inflammation in these patients. Herein, we found that
plasma levels of LPS were significantly correlated with TMAO
and the TMA precursors carnitine and y-BB in CVID patients
(Figures 6A–C), indicating a relation between gut leakage and
TMAO pathway metabolites.
Similar to CVID, patients with selective IgA deficiency
also have lower gut microbial diversity (28), thus it is of
interest to explore whether undetectable serum IgA levels
could influence TMAO concentrations in CVID patients. We
compared CVID patients with undetectable serum IgA levels
(IgA < 0.1 g/L) to CVID patients with detectable serum IgA
levels (IgA ≥ 0.1g /L) and found no significant difference in
plasma TMAO concentration between these two groups (p =
0.844, Supplementary Table 5). This may be due to a cut-off level
for serum IgA of <0.1 g/L being too strict (28), and that low,
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FIGURE 6 | Correlations between carnitine-TMAO metabolites and LPS. Plasma levels of LPS correlate positively with (A) TMAO, (B) Carnitine, and (C)
y-Butyrobetaine in CVID patients (n = 104). Two-tailed p-values were calculated using Spearman’s rank correlation.
but detectable, serum levels of IgA could still affect gut microbial
composition in CVID, and thereby TMAO levels.
Furthermore, LPS and low serum IgA concentrations have
been found to correlate with development of autoimmune
cytopenias in CVID patients (31, 32). We found no significant
difference in LPS levels between CVID patients with serum IgA
<0.1 g/L compared to CVID patients with IgA ≥ 0.1 g/L, or
CVID patients with or without autoimmune cytopenia, organ
specific autoimmunity or enteropathy (Supplementary Table 6).
To further look into the potential role of LPS and undetectable
serum IgA levels in the immunopathogenesis of CVID, we
investigated certain inflammatory cytokines in relation to these
markers. LPS correlated positively with IL-6 (p = 0.028, r
= 0.216), a central cytokine in the pathogenesis of several
autoimmune disorders as well as of inflammation in CVID (4),
but not did not correlate significantly with IL-8 (p = 0.192, rho
= 0.129), IL-12 (p = 0.064, rho = 0.182), or TNFα (p = 0.143,
rho = 0.145). Additional correlation analyses between LPS and
cytokines are given in Supplementary Table 7. Cytokine analyses
of CVID patients with serum IgA < 0.1 g/L compared to CVID
patients with IgA ≥ 0.1 g/L showed increased concentrations of
two chemokines involved in inflammatory processes (i.e., IP-10
andMCP-1) in patients with IgA< 0.1 g/L, but did not display an
overall different pattern in cytokine levels than those with IgA ≥
0.1 g/L (Supplementary Table 8). To conclude, the link between
LPS and inflammation in CVID could appear to occur on an
overall group level. However, low IgA levels may be of greater
importance than demonstrated here, conditional upon the cut-off
used for low/undetectable levels of serum IgA.
TMAO in Relation to Diet
A detailed self-reported food frequency questionnaire was
obtained from 38 CVID patients. Food items that have
been described to be associated with metabolites in the
carnitine-TMAO pathway include meat, fish, eggs, and dairy
products. CVID patients did not appear to consume more
of these food items compared to a reference population (33)
(Supplementary Figure 2). Hence, an increased consumption by
CVID patients of egg, dairy products, meat, or fish did not
appear to be responsible for the increased TMAO concentrations
seen in these patients. Additionally, we investigated other food
items relevant to gut microbiota and inflammation such as
fiber, protein, wine, and sugar (34–36) for association analyses
with TMAO. Wine consumption correlated negatively with
TMAO (p = 0.023, rho = −0.37) in CVID patients, and
when separating wine consumption into red wine and white
wine, the negative correlation with TMAO, corrected for age
and sex, remained significant only for red wine (p = 0.018,
β = −0.332). We also found that intake of table sugar, but
not total sugar consumption, was associated with increased
plasma concentrations of TMAO (p = 0.006, rho = 0.44). In
contrast, dietary intake of meat, fish, egg, dairy products, and
fiber were not found significantly associated with TMAO in
plasma (Supplementary Table 9), further supporting that other
mechanisms than diet are responsible for the increased TMAO
in CVID.
TMAO in Relation to Rifaximin Use
It has previously been shown that a course of short-term
antibiotics such as ciprofloxacin and metronidazole can reduce
TMAO concentrations in plasma of healthy humans, as well
as in mouse models of cardiovascular disease (administering
vancomycin, neomycin sulfate, metronidazole, or ampicillin for
3 weeks) (37, 38). We have previously shown that a 2-week
course of the broad spectrum oral antibiotic rifaximin alters
gut microbial composition, but not systemic inflammation in
CVID (23). Based on the knowledge that rifaximin acts purely
locally in the gut and that several antibiotics have previously
been demonstrated to influence TMAO concentrations, it was
intriguing to investigate whether rifaximin (550mg twice-
daily) could have a similar impact. We therefore measured
the effect of 2 week administration of rifaximin on plasma
concentrations of TMAO in 40 CVID patients and found
that there was no difference in TMAO concentrations between
the rifaximin intervention group (n = 20) (baseline 5.0 [3.5–
6.2] µmol/L, 2 weeks 4.3 [2.7–7.0] µmol/L, and 6 weeks
4.4 [3.1–6.9] µmol/L) and the no intervention group (n =
20) (baseline 3.2 [2.0–5.5] µmol/L, 2 weeks 5.5 [2.5–9.0]
µmol/L, and 6 weeks 3.6 [1.9–11.2] µmol/L), p = 0.975
(UNIANOVA), data are given in median (25–75 percentile)
(Supplementary Figure 3).
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TMAO in Relation to Clinical
Characteristics of the CVID Patients
When dividing the CVID patients (n = 104) into two
main subgroups by phenotype (i.e., infection only [n =
25] and those with non-infectious inflammatory and/or
autoimmune complications [n = 79]), we found no differences
in TMAO concentration between “infection only” (6.2 ±
4.0 µmol/L) vs. “non-infectious complications” (7.3 ± 7.3
µmol/L, mean ± SD), p = 0.922. Specific analyses of CVID
subgroups including autoimmune cytopenia, organ-specific
autoimmunity, and enteropathy did not show significant
differences in TMAO concentration between patients with
and without these features (Supplementary Table 9). Only
two of the 104 CVID patients were not on Ig-replacement
therapy and notably, these two were not outliers in the
plasma TMAO concentration data (both had plasma TMAO
concentration <15 µmol/L).
Both age and sex correlated significantly with metabolites in
the carnitine-TMAO pathway in CVID patients and controls (p
< 0.001, rho = 0.36 and p = 0.02, rho = 0.24, respectively), and
were therefore adjusted for in statistical analyses (see Methods).
BMI has previously been found to correlate positively with
TMAO in some studies (39, 40), but we did not find this in
our dataset (p = 0.802, rho = −0.03). Finally, kidney function
could potentially influence TMAO concentrations. We therefore
explored if there was any difference in estimated glomerular
filtration rate (eGFR) between CVID patients and controls, which
could potentially have been a confounding factor. We found no
significant difference in eGFR between the patients and controls
(59.4 ± 4.2 vs. 60.0 ± 0.0, mean ± SD), p = 0.277. Interestingly,
within the CVID group, we found no significant difference in
plasma TMAO concentration between those with eGFR < 60 vs.
those with eGFR > 60 (11.1 ± 6.4 vs. 6.9 ± 6.7 µmol/L, mean ±
SD, p= 0.082).
DISCUSSION
This is, to the best of our knowledge, the first study measuring
TMAO and its related metabolites in CVID. The main findings
of this study were: (i) CVID patients had persistently elevated
plasma concentrations of TMAO and its precursors carnitine,
choline, betaine as well as its intermediate metabolite y-
BB compared to healthy controls; (ii) TMAO concentrations
were positively correlated with TNFα and IL-12, representing
prototypical inflammatorymarkers in CVID; (iii) The abundance
of Gammaproteobacteria in stool and LPS in plasma were
associated with increased concentrations of TMAO in CVID,
furthermore bacterial genes CntA and CutC encoding TMA
producing enzymes were more abundant in the gut microbiota of
CVID patients than in controls. Our findings suggest that TMAO
could be a link between disturbed gut microbiota and systemic
inflammation in CVID.
The plasma concentrations of TMAO are influenced by
several factors, including diet, gut microbiota, and kidney
function (11, 41). In the present study, CVID patients were
characterized by high TMAO concentrations, correlating with
systemic inflammation and certain key bacteria related to the
gut dysbiosis in CVID, as well as with LPS thought to reflect
gut leakage mechanisms. In contrast, we did not find significant
associations with kidney function or dietary intake of major
food groups. Increased TMAO concentrations have previously
been reported in several metabolic disorders, e.g., T2DM, obesity,
and cardiovascular disease, and has also been shown to predict
cardiovascular disease risk and outcome (42). However, increased
TMAO concentrations have also been linked to other diseases
such as HIV, irrespective of cardiovascular disease, where the
increase in TMAO has been associated with altered gut microbial
composition and systemic inflammation (43). Herein, we report
a similar pattern in CVID, with increased TMAO concentrations
associated with immune activation, gut microbial dysbiosis, and
elevated LPS (Figure 1B).
A key question is whether TMAO is not only a marker
but also a mediator of inflammation (44). Mechanistic studies
have demonstrated that TMAO triggers activation of the
NLRP3 inflammasome in endothelial cells, involving increased
production of reactive oxygen species (45, 46). In addition,
mice studies have demonstrated that dietary supplements of
TMAO result in reduced reverse cholesterol transport in vivo
(47), which could potentially promote inflammation. In line
with this, we have recently shown that CVID patients with
non-infectious complications have impaired reverse cholesterol
transport, potentially contributing to systemic inflammation in
these patients (48).
We found a positive association between abundance of
Gammaproteobacteria and Escherichia-Shigella in the gut
microbiome of CVID patients and concentrations of TMAO
in plasma. Supporting our findings, Gammaproteobacteria
have previously been shown to produce TMA in the gut of
HIV-infected patients (43). Administration of oral rifaximin for
2 weeks did not significantly alter plasma TMAO concentrations
in CVID patients, likely due to a lack of effect on central gut
microbes (23) involved in TMA production. The increased
amount of TMA producing enzyme CntA in stool samples from
CVID patients compared to controls fits well with the association
of increased Gammaproteobacteria and TMAO concentrations
in CVID. However, since CntA amplicons display high identities
(∼99%) to Gammaproteobacteria-derived references (primarily
from Escherichia coli) (12), it is difficult to separate the association
with CntA from the association with Gammaproteobacteria.
CutC amplicons have been associated with various taxa (e.g.,
Clostridium XIVa strains), but many sequences are not identified,
suggesting that key human TMA producers are yet to be isolated
(12). It is however important to remember that the abundance
of CntA and CutC has previously been described to encompass
<1% of the total bacterial community (12). The additional
mechanism, where gut microbiota converts carnitine to TMA
via the intermediate γBB, may be an equally important route
for TMA formation from carnitine in the human gut (49). This
is illustrated by the increased plasma concentrations of γBB
in CVID compared to controls and the positive association of
plasma γBB to Escherichia-Shigella in stool samples. Of note,
bacterial genes involved in the two-step process with γBB are
unknown and were therefore not investigated further (49).
Differences in intake of food items such as meat, fish, eggs,
and dairy products, known to increase TMAO and its related
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metabolites cannot explain the increased TMAO concentration
seen in CVID patients compared to controls. In the present study,
there were no associations between the main components of the
diet (i.e., meat, fish, dairy products, and fiber) and TMAO in the
CVID patients. The negative correlation between consumption
of red wine and plasma TMAO is however noteworthy, since
red wine may contain compounds inhibiting of microbial TMA
formation, such as DMB (3,3-dimethyl-1-butanol), reducing the
potential for hepatic TMAO synthesis (50, 51). However, the lack
of association of food items known to increase TMAO and related
metabolites underscores that the high TMAO concentrations in
CVID are not related to diet, but more likely related to gut
microbial composition.
The strengths of this study, compared to other TMAO studies,
are the inclusion of gut microbiota and dietary data allowing
us to investigate carnitine-TMAO pathway metabolites in more
detail. In addition, the total number of patients in the TMAO
metabolite and inflammatory marker analyses was substantial,
considering the prevalence of CVID. The limitations of this study
are not having dietary information and gut microbial data on
all CVID patients, as well as a small sized control group for the
plasma/serum analyses compared to the control group for the
microbiota analyses in stool. Furthermore, associations do not
necessarily signify causal relationship, thus mechanistic studies
are needed to further explore the role of TMAO in persistent
inflammation and immune activation such as seen in CVID.
In conclusion, plasma TMAO concentrations are elevated in
CVID patients compared to healthy controls, correlating with
markers of systemic inflammation and gut microbial abundance
of Gammaproteobacteria. These patients also have increased
amounts of gut bacterial genes CntA and CutC, encoding TMA
producing enzymes. We suggest that TMAO could be a link
between disturbed gut microbiota and systemic inflammation in
CVID, and that its relation to certain key bacteria indicates that
gut microbiota could be a therapeutic target to reduce TMAO
formation and thereby systemic inflammation in CVID.
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